Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2015 | Research article

Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats

Authors: Yue-Hua Wang, Yan-Hong Liu, Guo-Rong He, Yang Lv, Guan-Hua Du

Published in: BMC Complementary Medicine and Therapies | Issue 1/2015

Abstract

Background

Increasing studies have shown that dyslipidemia and inflammatory responses play important roles in the progression of microvascular diabetic complications. Esculin (ES), a coumarin derivative, was extracted from Fraxinus rhynchophylla. The present study was to evaluate the potential effects of ES on lipid metabolism, inflammation responses and renal damage in streptozotocin (STZ)-induced experimental diabetic rats and explore the possible mechanism.

Methods

Diabetic rat model was established by administration high-glucose-fat diet and intraperitoneal injection of STZ 45 mg/kg. ES was administrated to diabetic rats intragastrically at 10, 30 and 90 mg/kg for 10 weeks respectively. The levels of triglycerides (TG), total cholesterol (T-CHO), low density lipoproteins (LDL), and high-density-cholesterol (HDL-C) in serum were measured. IL-1, IL-6, ICAM-1, NO, NAGL, and AGEs level in serum were detected by ELISA assay. The accumulation of AGEs in kidney tissue was examined by immunohistochemistry assay.

Results

The results showed that ES could decrease TG, T-CHO, LDL levels in serum of diabetic rats in a dose dependent manner. ES also decreased IL-1, IL-6, ICAM-1, NO and NGAL levels in serum of diabetic rats in a dose dependent manner. Furthermore, ES at 30 and 90 mg/kg significantly decreased AGEs level in serum and alleviated AGEs accumulation in renal in diabetic rats.

Conclusions

Our findings indicate that ES could improve dyslipidemia, inflammation responses, renal damage in STZ-induced diabetic rats and the possible mechanism might be associated with the inhibition of AGEs formation.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed

Kulkarni CR, Joglekar MM, Patil SB, Arvindekar AU (2012) Antihyperglycemic and antihyperlipidemic effect of Santalum album in streptozotocin induced diabetic rats. Pharm Biol 50:360–365CrossRefPubMed

Ansar S, Koska J, Reaven PD (2011) Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 10:61CrossRefPubMedPubMedCentral

Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P, Mauer M, Fioretto P (2000) Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 4:8–14

Soni SS, Cruz D, Bobek I, Chionh CY, Nalesso F, Lentini P, de Cal M, Corradi V, Virzi G, Ronco C (2010) NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol 42:141–150CrossRefPubMed

Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238CrossRefPubMed

Takeuchi M, Yamagishi S (2009) Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease. J Alzheimers Dis 16:845–858PubMed

Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749CrossRefPubMed

Jung HA, Park JJ, Islam MN, Jin SE, Min BS, Lee JH, Sohn HS, Choi JS (2012) Inhibitory activity of coumarins from Artemisia capillaris against advanced glycation endproduct formation. Arch Pharm Res 35:1021–1035CrossRefPubMed

10.

Nurul Islam M, Jung HA, Sohn HS, Jin SE, Min BS, Lee JH, Sohn HS, Choi JS (2013) Potent α-glucosidase and protein tyrosine phosphatase 1B inhibitors from Artemisia capillaris. Arch Pharm Res 36:542–552CrossRefPubMed

11.

Kang KS, Lee W, Jung Y, Lee JH, Lee S, Eom DW, Jeon Y, Yoo HH, Jin MJ, Song KI, Kim WJ, Ham J, Kim HJ, Kim SN (2014) Protective effect of esculin on streptozotocin-induced diabetic renal damage in mice. J Agric Food Chem 62:2069–2076CrossRefPubMed

12.

Shepherd J, Kastelein JJP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK (2008) Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 83:870–879CrossRefPubMed

13.

Tiwari S, Riazi S, Elcebarger CA (2007) Insulin’s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Ren Physiol 293:F974–F984CrossRef

14.

Louro TM, Matafome PN, Nunes EC, da Cunha FX, Seiça RM (2011) Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol 653:89–94CrossRefPubMed

15.

Balakumar P, Chakkarwar VA, Krishan P, Singh M (2009) Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother 63:171–179CrossRefPubMed

16.

Early KA, Harry D, Zitouni K (2008) Circulating cholesterol as a modulator of risk for renal injury in patients with type 2 diabetes. Diab Res Clin Pract 79:68–73CrossRef

17.

Cahde AR, Lerman A, Lerman LO (2005) Kidney in early atherosclerosis. Hypertension 45:1042–1049CrossRef

18.

Grone EF, Grone HJ (2008) Does hyperlipidemia injure the kidney? Nat Clin Pract Nephrol 4:424–425CrossRefPubMed

19.

Pokharel YR, Lee MY, Kim SK, Bae K, Su ND, Oh WK, Kang KW (2009) Dual anti-oxidative effects of fraxetin isolated from fraxinus rhinchophylla. Biol Pharm Bul 32:1527–1532CrossRef

20.

Naaz F, Abdin MZ, Javed S (2014) Protective effect of esculin against prooxidant aflatoxin B1 -induced nephrotoxicity in mice. Mycotoxin Res 30:25–32CrossRefPubMed

21.

Cardellini M, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Perticone F, Federici M, Lauro D, Sesti G (2007) Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive offspring of type 2 diabetic patients. Am J Physiol Endocrinol Metab 292:E347–E352CrossRefPubMed

22.

Kadian S, Mahadevan N, Balakumar P (2013) Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. Eur J Pharmacol 698:388–396CrossRefPubMed

23.

Pei F, Li BY, Zhang Z, Yu F, Li XL, Lu WD, Cai Q, Gao HQ, Shen L (2014) Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice. J Diabetes Complications 28:596–603CrossRefPubMed

24.

Grandhee SK, Monnier VM (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266:11649–11653PubMed

25.

Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ (2005) Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28:2465–2471CrossRefPubMed

26.

Jandeleit-Dahm K, Watson A, Soro-Paavonen A (2008) The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol 35:329–334CrossRefPubMed

27.

Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103–3111CrossRefPubMedPubMedCentral

28.

Nożyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M (2012) Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant 17:53–61CrossRefPubMed

29.

Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54:3274–3281CrossRefPubMed

30.

Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752CrossRefPubMedPubMedCentral

31.

Fukami K, Yamagishi S, Coughlan MT, Harcourt BE, Kantharidis P, Thallas-Bonke V, Okuda S, Cooper ME, Forbes JM (2014) Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr 6:86CrossRefPubMedPubMedCentral

32.

Fukami K, Yamagishi S, Ueda S, Okuda S (2008) Role of AGEs in diabetic nephropathy. Curr Pharm Des 14:946–952CrossRefPubMed

33.

Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T (2008) Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 40:10–15CrossRefPubMed

34.

Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12:562–572CrossRefPubMed

35.

Nakashima S, Matsui T, Takeuchi M, Yamagishi SI (2014) Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 46:717–721CrossRefPubMed

Title: Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats
Authors: Yue-Hua Wang
Yan-Hong Liu
Guo-Rong He
Yang Lv
Guan-Hua Du
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2015
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-015-0817-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

The obesity-risk variant of FTO is inversely related with the So-Eum constitutional type: genome-wide association and replication analyses

Antinociceptive effect of methanol extract of leaves of Persicaria hydropiper in mice

A survey among Korea Medicine doctors (KMDs) in Korea on patterns of integrative Korean Medicine practice for lumbar intervertebral disc displacement: Preliminary research for clinical practice guidelines

Erratum to: Arum Palaestinum with isovanillin, linolenic acid and β-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice

The use of Piper sarmentosum leaves aqueous extract (Kadukmy™) as antihypertensive agent in spontaneous hypertensive rats

Green tea extract and its major constituent epigallocatechin-3-gallate inhibit growth and halitosis-related properties of Solobacterium moorei